BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22487084)

  • 1. Differential sensitivity of von Willebrand factor (VWF) 'activity' assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays.
    Favaloro EJ; Bonar R; Chapman K; Meiring M; Funk Adcock D
    J Thromb Haemost; 2012 Jun; 10(6):1043-54. PubMed ID: 22487084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: A large international cross-laboratory study.
    Favaloro EJ; Bonar R; Hollestelle MJ; Jennings I; Mohammed S; Meijer P; Woods T; Meiring M
    Thromb Res; 2018 Jun; 166():96-105. PubMed ID: 29727738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease.
    Favaloro EJ; Mohammed S
    Thromb Res; 2016 May; 141():202-11. PubMed ID: 26743192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards improved diagnosis of von Willebrand disease: comparative evaluations of several automated von Willebrand factor antigen and activity assays.
    Favaloro EJ; Mohammed S
    Thromb Res; 2014 Dec; 134(6):1292-300. PubMed ID: 25300811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of von Willebrand factor (VWF) activity levels determined by HemosIL AcuStar assay and HemosIL LIA assay with ristocetin cofactor assay by aggregometry.
    Sagheer S; Rodgers S; Yacoub O; Dauer R; Mcrae S; Duncan E
    Haemophilia; 2016 May; 22(3):e200-7. PubMed ID: 27076201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative analysis of different automated von Willebrand factor glycoprotein Ib-binding activity assays in well typed von Willebrand disease patients.
    Vangenechten I; Mayger K; Smejkal P; Zapletal O; Michiels JJ; Moore GW; Gadisseur A
    J Thromb Haemost; 2018 Jul; 16(7):1268-1277. PubMed ID: 29742318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
    Turecek PL; Siekmann J; Schwarz HP
    Semin Thromb Hemost; 2002 Apr; 28(2):149-60. PubMed ID: 11992238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A highly-sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry.
    Chen D; Daigh CA; Hendricksen JI; Pruthi RK; Nichols WL; Heit JA; Owen WG
    J Thromb Haemost; 2008 Feb; 6(2):323-30. PubMed ID: 18031294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
    Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay.
    Riddell AF; Jenkins PV; Nitu-Whalley IC; McCraw AH; Lee CA; Brown SA
    Br J Haematol; 2002 Jan; 116(1):187-92. PubMed ID: 11841416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
    Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R
    Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin.
    Graf L; Moffat KA; Carlino SA; Chan AK; Iorio A; Giulivi A; Hayward CP
    Int J Lab Hematol; 2014 Jun; 36(3):341-51. PubMed ID: 24750681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new flow cytometric method for measurement of von Willebrand factor activity.
    Lindahl TL; Fagerberg IH; Larsson A
    Scand J Clin Lab Invest; 2003; 63(3):217-23. PubMed ID: 12817908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of two new automated assays for measuring von Willebrand activity: HemosIL AcuStar and Innovance.
    de Maistre E; Volot F; Mourey G; Aho LS; Ternisien C; Briquel ME; Bertrand MA; Tardy B; Frotscher B; Nguyen P; Dumont L; Vandroux D; Hézard N; Trossaërt M
    Thromb Haemost; 2014 Oct; 112(4):825-30. PubMed ID: 25103956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays.
    Favaloro EJ
    Blood Coagul Fibrinolysis; 2011 Oct; 22(7):553-64. PubMed ID: 21885953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Technological advances in diagnostic testing for von Willebrand disease: new approaches and challenges.
    Hayward CP; Moffat KA; Graf L
    Int J Lab Hematol; 2014 Jun; 36(3):334-40. PubMed ID: 24750680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis or Exclusion of von Willebrand Disease Using Laboratory Testing.
    Favaloro EJ
    Methods Mol Biol; 2017; 1646():391-402. PubMed ID: 28804843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen.
    Stufano F; Lawrie AS; La Marca S; Berbenni C; Baronciani L; Peyvandi F
    Haemophilia; 2014 Jan; 20(1):147-53. PubMed ID: 24028703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity?
    Casonato A; Pontara E; Bertomoro A; Sartorello F; Cattini MG; Girolami A
    Br J Haematol; 2001 Mar; 112(3):578-83. PubMed ID: 11260057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease.
    Favaloro EJ
    Thromb Haemost; 2010 Nov; 104(5):1009-21. PubMed ID: 20806123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.